drugset / Trial / NCT01206439

An Advanced Echocardiographic Evaluation of Nebivolol

NCT01206439

Phase 4 Terminated 2 enrolled Jack Rubinstein Forest Laboratories · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if Nebivolol has any effect on heart function determined by changes in echocardiographic data or exercise tolerance.

Timeline

Start
2010-09
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nebivolol Other / unclassified 5 mg Oral
Subject Nebivolol Other / unclassified 10 mg Oral

Indications